Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04289259 | Tumor Mutational Burden in Lung Cancer Patients(MUBULUC) | terminated | — | 6 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 24, 2021 | clinicaltrials |
| NCT02349633 | Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) | terminated | Phase 1 / Phase 2 | 65 | PfizerINDUSTRY | 4 | Jun 10, 2021 | clinicaltrials |
| NCT02768558 | Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC | terminated | Phase 3 | 20 | RTOG Foundation, Inc.OTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT02274038 | Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer | terminated | N/A | 3 | University of PennsylvaniaOTHER | 1 | May 12, 2021 | clinicaltrials |
| NCT02621333 | Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma | terminated | Phase 2 | 280 | Henan Cancer HospitalOTHER_GOV | 1 | May 12, 2021 | clinicaltrials |
| NCT01244191 | Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer | terminated | Phase 3 | 1,048 | Daiichi SankyoINDUSTRY | 23 | Apr 6, 2021 | clinicaltrials |
| NCT03644823 | Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC(COM-IT-1) | terminated | Phase 2 | 21 | Oslo University HospitalOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT02608528 | Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy | terminated | — | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT02132598 | Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases | terminated | Phase 2 | 5 | Liza Villaruz, MDOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT01212627 | Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer | terminated | Phase 1 | 12 | Angela Taber MDOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT02400424 | Study of the Efficacy of SBRT on Unresectable Peripheral Primary Tumor(GFPC_01-14) | terminated | N/A | 25 | Centre Leon BerardOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT03256721 | Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC | terminated | Phase 2 | 37 | Fuzhou General HospitalOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT02893332 | Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)(Sindas) | terminated | Phase 3 | 200 | Sichuan Provincial People's HospitalOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT03125200 | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression | terminated | Phase 1 | 21 | ADC Therapeutics S.A.INDUSTRY | 2 | Feb 1, 2021 | clinicaltrials |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) | terminated | Phase 1 | 13 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 27, 2021 | clinicaltrials |
| NCT02262000 | Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer(SABR) | terminated | N/A | 3 | West Virginia UniversityOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT02485652 | Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung | terminated | Phase 2 | 162 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 10 | Jan 22, 2021 | clinicaltrials |
| NCT03382899 | Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer(Cypress 1) | terminated | Phase 2 | 101 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04170959 | The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC(RADFORMIN) | terminated | Phase 2 | 3 | ethisch.comite@uza.beOTHER | 1 | Jan 15, 2021 | clinicaltrials |
| NCT00760929 | A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC). | terminated | Phase 2 | 171 | Hoffmann-La RocheINDUSTRY | 11 | Jan 5, 2021 | clinicaltrials |
| NCT00662597 | ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer(ATRACT-1) | terminated | Phase 3 | 1,285 | Novartis PharmaceuticalsINDUSTRY | 26 | Dec 24, 2020 | clinicaltrials |
| NCT00738387 | A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer(ATTRACT-2) | terminated | Phase 3 | 900 | Novartis PharmaceuticalsINDUSTRY | 10 | Dec 24, 2020 | clinicaltrials |
| NCT01268059 | A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 99 | MedImmune LLCINDUSTRY | 7 | Dec 23, 2020 | clinicaltrials |
| NCT00480025 | GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer | terminated | Phase 3 | 2,278 | GlaxoSmithKlineINDUSTRY | 34 | Dec 22, 2020 | clinicaltrials |
| NCT03603652 | NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung | terminated | N/A | 10 | Ethicon, Inc.INDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT03246854 | A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer | terminated | Phase 1 | 6 | National Health Research Institutes, TaiwanOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT00794417 | A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma | terminated | Phase 1 / Phase 2 | 60 | Regeneron PharmaceuticalsINDUSTRY | 2 | Dec 10, 2020 | clinicaltrials |
| NCT00269828 | A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.(PIONEER) | terminated | Phase 3 | 600 | CTI BioPharmaINDUSTRY | 11 | Nov 24, 2020 | clinicaltrials |
| NCT03553550 | Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation(LIBERTI) | terminated | — | 38 | Addario Lung Cancer Medical InstituteOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT02762877 | Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer | terminated | — | 140 | Genomic Health®, Inc.INDUSTRY | 7 | Nov 17, 2020 | clinicaltrials |
| NCT04044170 | Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | terminated | Phase 2 | 5 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 2 | Nov 17, 2020 | clinicaltrials |
| NCT03302247 | Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy | terminated | Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)(NeoFIND) | terminated | Phase 2 | 19 | Advanced Accelerator ApplicationsINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT02318368 | A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label(FOCAL) | terminated | Phase 2 | 10 | AVEO Pharmaceuticals, Inc.INDUSTRY | 7 | Oct 22, 2020 | clinicaltrials |
| NCT01188707 | A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 5 | Herlev HospitalOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | terminated | Phase 1 | 5 | Fore BiotherapeuticsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02642939 | Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer | terminated | Phase 2 | 3 | Check, Jerome H., M.D., Ph.D.INDIV | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(TRAP) | terminated | Phase 1 | 85 | Polaris GroupINDUSTRY | 2 | Sep 25, 2020 | clinicaltrials |
| NCT02145078 | Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer | terminated | N/A | 4 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT01532362 | Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer | terminated | N/A | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 22, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT03382912 | Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer(Cypress 2) | terminated | Phase 2 | 52 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 11, 2020 | clinicaltrials |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | terminated | Phase 1 | 27 | Famewave Ltd.INDUSTRY | 2 | Aug 27, 2020 | clinicaltrials |
| NCT02147990 | Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer(NSCLC) | terminated | Phase 2 | 318 | Clovis Oncology, Inc.INDUSTRY | 12 | Aug 12, 2020 | clinicaltrials |
| NCT04510415 | Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI | terminated | Phase 1 | 2 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Aug 12, 2020 | clinicaltrials |
| NCT01526928 | Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients | terminated | Phase 1 / Phase 2 | 612 | Clovis Oncology, Inc.INDUSTRY | 4 | Aug 4, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03745222 | A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer(RATIONALE001) | terminated | Phase 3 | 1 | CelgeneINDUSTRY | 23 | Jul 15, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Jun 24, 2021source: clinicaltrials